Buy Daliresp

Daliresp

Daliresp: A Comprehensive Guide to Roflumilast for Adults

1. Introduction - What Is Daliresp?

Daliresp is a brand-name medication that contains the active ingredient roflumilast. It belongs to the therapeutic class of phosphodiesterase-4 (PDE4) inhibitors and is formulated as a pill for oral use. In the United Kingdom, Daliresp is a prescription-only (POM) product regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). The tablet is marketed in a single strength of 500 µg (0.5 mg).

Roflumilast is used primarily to manage chronic respiratory conditions that involve airway inflammation, most notably severe chronic obstructive pulmonary disease (COPD) with chronic bronchitis. Although the broader category is listed as “Asthma & Breathing,” the drug’s approved indication focuses on COPD-related symptoms and the prevention of exacerbations.

2. Mechanism of Action - How Roflumilast Works

Roflumilast is a selective PDE4 inhibitor. PDE4 is an enzyme found in inflammatory cells of the lung (such as neutrophils, eosinophils, macrophages, and T-lymphocytes). By blocking PDE4, roflumilast increases intracellular cyclic adenosine monophosphate (cAMP) levels. Elevated cAMP dampens the release of pro-inflammatory mediators (e.g., tumour necrosis factor-α, interleukins) and reduces recruitment of inflammatory cells to the airways.

The net effect is a decrease in chronic airway inflammation, which helps to lower the frequency of COPD exacerbations and improves overall lung function. Roflumilast’s anti-inflammatory action is distinct from bronchodilators, which primarily relax airway smooth muscle.

Key pharmacokinetic points (in plain language):

• Onset: Anti-inflammatory effects become measurable within a few days, but the full benefit on exacerbation risk is usually seen after several weeks.
• Peak plasma concentration: Approximately 1-2 hours after ingestion.
• Duration: The drug’s half-life is around 17 hours, supporting once-daily dosing.
• Metabolism: Primarily hepatic via the CYP3A4 pathway, producing an active metabolite (roflumilast-N-oxide).

3. Approved Medical Uses - When Is Daliresp Prescribed?

Primary indication (MHRA-approved):

• Maintenance treatment of severe COPD in adults who have chronic bronchitis and a history of frequent exacerbations, to reduce the risk of further exacerbations.

Typical patient profile:

• Adults (≥ 18 years) with a confirmed diagnosis of COPD, chronic productive cough, and at least two exacerbations in the previous year despite optimal bronchodilator therapy.

Note: Daliresp is not approved for the treatment of asthma in the UK. Its use in asthma is considered off-label and should only be contemplated under specialist supervision when evidence supports a potential benefit.

4. Off-Label and Investigational Applications

Potential off-label uses:

• Asthma with a predominant inflammatory phenotype: Small clinical studies have explored roflumilast as an add-on therapy for severe, refractory asthma, showing modest improvements in lung function and symptom control.
• COPD-related pulmonary hypertension: Early-phase research suggests anti-inflammatory benefits may translate to hemodynamic improvements, though data remain limited.

Regulatory status: These applications are not approved by the MHRA and must be prescribed only after a thorough risk-benefit assessment by a respiratory specialist.

Disclaimer: Off-label use requires medical supervision and individualized risk assessment; patients should discuss potential benefits and risks with their healthcare provider.

5. Patient Suitability and Contraindications

Who Should Use Daliresp?

• Adults with severe COPD and chronic bronchitis who continue to experience frequent exacerbations despite optimal inhaled therapy.
• Patients who can tolerate oral medication and have no significant hepatic impairment.

Absolute Contraindications

• Known hypersensitivity to roflumilast or any excipients in the tablet.
• Severe liver disease (Child-Pugh class C).
• Pregnancy - roflumilast is classified as pregnancy category X in the UK; it should not be used during pregnancy.

Relative Contraindications / Precautions

• Moderate hepatic impairment (Child-Pugh class B) - use only if benefits outweigh risks.
• Renal impairment (eGFR < 30 mL/min) - dose adjustment is not recommended; monitor closely.
• Weight loss or low body-mass index - roflumilast can cause further weight reduction.
• History of depression or suicidal thoughts - increased vigilance is required.

Special Populations

• Breast-feeding: Roflumilast is excreted in breast-milk; breastfeeding should be avoided.
• Elderly: No specific dose reduction, but monitor for side effects such as diarrhea and weight loss.

6. Safety Profile - Side Effects and Interactions

Common Side Effects

• Diarrhea (often mild to moderate)
• Nausea and vomiting
• Headache
• Insomnia or disturbed sleep
• Weight loss (average 1-2 kg over several weeks)

These effects are usually transient and may improve with continued therapy. Maintaining adequate hydration and a balanced diet can help mitigate gastrointestinal symptoms.

Serious Adverse Events

• Psychiatric disturbances: Depression, anxiety, and rare suicidal ideation. Promptly report mood changes.
• Severe hepatic injury: Elevated transaminases; routine liver-function monitoring is essential.
• Allergic reactions: Rash, urticaria, or anaphylaxis in rare cases.

Major Drug Interactions

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, HIV protease inhibitors) can increase roflumilast plasma concentrations → higher risk of adverse effects.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine, St. John’s Wort) may reduce efficacy → consider alternative therapy.
• Warfarin: Roflumilast may increase INR; monitor coagulation parameters when co-administered.

Food and Lifestyle Interactions

• Take with breakfast to reduce gastrointestinal upset.
• Alcohol: No specific restriction, but excessive intake may worsen liver function.
• Driving: Roflumilast does not impair psychomotor performance, but if insomnia or dizziness occurs, exercise caution.

If patients are taking multiple medicines, supplements, or herbal products, they should inform their healthcare provider before starting Daliresp.

7. Dosing and Administration Guidelines

• Standard dose: One 500 µg (0.5 mg) tablet taken once daily, preferably with the first main meal of the day.
• Missed dose: If a dose is forgotten, skip it and resume the regular schedule the next day; do not double the dose.
• Overdose: Symptoms may include severe nausea, vomiting, diarrhea, and possible weight loss. Seek emergency medical care; treatment is supportive.
• Renal or hepatic adjustment: No routine dose reduction is recommended; however, patients with severe hepatic impairment should avoid the medication.

Administration tips:

• Swallow the tablet whole; do not crush or chew.
• Store at room temperature, protected from moisture and heat.

8. Monitoring and Follow-Up

• Baseline liver function tests (ALT, AST, bilirubin) before initiating therapy.
• Repeat liver tests after 4-8 weeks, then periodically (e.g., every 3-6 months).
• Weight monitoring at each clinic visit; intervene if loss exceeds 5 % of baseline body weight.
• Psychiatric assessment: Evaluate mood and mental health at baseline and during follow-up, especially in patients with a prior history of depression.

If any laboratory abnormality or adverse event becomes significant, the prescriber may consider dose interruption or discontinuation.

9. Storage and Handling

• Keep the tablets in the original blister pack until use.
• Store at 20-25 °C (68-77 °F), away from direct sunlight and moisture.
• Do not use if the packaging is damaged or the tablets appear discoloured.
• Keep out of reach of children and pets.

10. Medication-Specific Glossary

Phosphodiesterase-4 (PDE4) inhibitor

A drug class that blocks the PDE4 enzyme, raising intracellular cAMP levels and reducing inflammatory cell activity in the lungs.

Chronic bronchitis

A form of COPD characterized by a productive cough for at least three months in two consecutive years, reflecting persistent airway inflammation.

Exacerbation

An acute worsening of respiratory symptoms that typically requires additional therapy, such as oral steroids or antibiotics, and may lead to hospitalisation.

Child-Pugh classification

A scoring system used to assess the severity of chronic liver disease; classes A (mild), B (moderate), and C (severe).

cAMP (cyclic adenosine monophosphate)

A cellular messenger that, when increased, suppresses inflammatory pathways in airway cells.

11. Medical Disclaimer

This article provides educational information about Daliresp (roflumilast) and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.

12. FAQ